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a b  s  t  r a  c  t
Since the  discovery  of the  influence of the  endocrine  system  on cardiac  endocrine  function 30 years
ago, an  increasing  number of experimental  and clinical  studies  have consolidated  endocrine function
of human  heart  as being  a relevant  component  of  a complex  network  including  endocrine,  nervous and
immune systems.  Many aspects,  however,  still  remain  unclear  as to the production,  secretion and  periph-
eral degradation  pathways of B- and  C-type natriuretic peptides.  In  particular, the hypothesis that  the
circulating  plasma pool of the pro-hormone  can  function as precursor of the active peptide hormone  is yet
to be fully  demonstrated.  According to recent studies,  peripheral  processing  of  circulating pro-hormone
likely undergoes regulation  pathways  which  seem to be impaired  in patients  with heart  failure. This
would open new perspectives also  in  the treatment  of heart  failure, and  identify novel  pharmacological
targets  for  drugs  inducing and/or  modulating  the maturation  of the  pro-hormone  into active  hormone.
© 2013 Elsevier Ltd. All rights reserved.
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1. Introduction
The cardiac endocrine function was first discovered 30 years
ago [1,2]. Since then, an increasing number of experimental and
clinical studies have been performed on  the topic, and a recent
search on this field the key words “cardiac natriuretic peptides”
on PubMed performed in May  2013 produced over 13,900 results,
(last access May  2013). Overall, many advances have been made
in the field, consolidating the endocrine function of  human heart
as being a relevant component of a complex network including
∗ Corresponding author at:  Laboratory of Cardiovascular Biochemistry, Institute
of  Clinical Physiology – National Research Council, Via Giuseppe Moruzzi 1, 56124
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endocrine, nervous and immune systems. Yet, many key aspects
have remained unsolved.
The first real breakthrough in research dates back to 1981
when de  Bold et  al. [1] reported intravenous injection of  atrial
extracts promoting a rapid and massive diuresis and natriuresis
in rats. Following that seminal study, a family of natriuretic and
vasodilator peptides was soon isolated, purified and within a few
years was chemically identified in human tissues [3–5].  To date,
research has identified, within this family of  peptides, a number
of different components: the atrial natriuretic peptide (ANP) and
the brain (or B-type) natriuretic peptide (BNP), predominantly
produced by  cardiomyocytes; the C-type natriuretic peptide (CNP)
predominantly produced by the endothelium; and urodilatin
produced by renal tubular cells by the same gene of ANP, and
which is found only in urine [3–5]. Most recently, a new peptide,
named Dendroaspis natriuretic peptide (DNP) has been identified
1043-6618/$ –  see front matter ©  2013 Elsevier Ltd. All rights reserved.
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Table 1
Some common clinical conditions characterized by altered plasma BNP circulating
levels, compared to healthy subjects.
Diseases BNP levels
(A) Cardiac disease
Heart failure Greatly increased
Acute myocardial infarction (first 2–5 days) Greatly increased











(D) Liver cirrhosis with ascites Increased
(E) Renal failure (acute or chronic) Greatly increased
(F) Paraneoplastic syndrome Normal or increased
(G) Subarachnoid hemorrhage Increased
(H) Use of cardiotoxic drugs Increased
(I) Acute sepsis Increased
(J) Chronic inflammatory disease (cardiac
impairment)
Increased
in mammalian plasma, but its pathophysiological relevance in
humans is still unclear [6].
All natriuretic peptides (NP) share a direct diuretic, natriuretic
and vasodilator effects and an inhibitory and protective action on
inflammatory processes of the myocardium, the endothelium and
of smooth muscle cells, thus modulating coagulation and fibrino-
lysis pathways, and inhibiting platelet activation [5–10].
A conspicuous number of  experimental and clinical studies
demonstrated that production and secretion of NP are closely
and subtly regulated by mechanical, chemical, neuro-hormonal
and immunological factors [1,3].  Plasma concentration of NP can
be considered as a sensitive index of the perturbation of the
homeostatic systems regulating cardiac function and cardiovas-
cular hemodynamics [3].  Given the important roles of the BNP in
both cardiovascular physiology and pathology, it is not surprising
that plasma BNP levels are increased in both cardiovascular and
extra-cardiovascular diseases (Table 1).
The clinical interest on the NP system has  enormously increased
after several meta-analyses and international guidelines recom-
mended measuring specific B-type-related natriuretic peptides for
diagnosis, risk stratification, and follow-up of patients with heart
failure [11–18].  Recent studies, however, are revealing that many B-
type natriuretic peptides measured in patients with cardiovascular
disease actually lack biological activity [2,5].  It appears rather that
plasma of patients with heart failure carries instead large amounts
of its pro-hormone peptide (i.e., proBNP) [19–28] suggesting a pos-
sible pathophysiological role of circulating proBNP levels in such
patients [2,5,29,30].  In particular, some authors have hypothesized
that the peripheral processing of circulating proBNP may  be sub-
ject to some regulatory process that is impaired in patients with
heart failure. If this were to be confirmed, it  would obviously set
new perspectives in the pharmacological treatment of heart failure
[2,5,29,30].
At the same time, recent studies suggest that CNP and its spe-
cific receptor, NPR-B, may play a very important role in regulating
cardiac hypertrophy and remodeling in patients with systemic
arterial hypertension, heart failure, and acute myocardial infarc-
tion [31,32].  The pathophysiological role of CNP on  cardiovascular
disease provides a rationale for the therapeutic potential of phar-
macological interventions targeted also to CNP system [33].
Here, we will review in detail some recent and still debated find-
ings regarding the role of NP system on cardiovascular diseases.
Table 2
Biological factors suggested to stimulate or inhibit the production/secretion of ANP
and  BNP in vivo or in  cell  culture of cardiomyocytes (modified from Ref. [2,3,5]).
Suggested factors Suggested mean intra-cellular
signaling mechanism
Stimulating
Mechanical strain Transcription factor NF-kB
activated by p38 MAPK
Angiotensin II  Transcription factor NF-kB
activated by p38 MAPK
Endothelin-1 Transcription factor NF-kB
activated by p38 MAPK
a-Adrenergic agents Transcription factor NF-kB
activated by p38 MAPK
Arginine vasopressin Ca2+ influx and PKC
Cytokines (including IL-1, IL-6, TNF-a)  Transcription factor NF-kB
activated by p38 MAPK
Growth factors (such as bFGF) MAPK
Prostaglandins (such as PGF2a and  PGD2) PLC, IP3, PKC, and MLCK
pathway
Lipolysaccharide (LPS) Transcription factor NF-kB
activated by p38 MAPK
Chromogranin B  Transcription factor NF-kB and
IP3/Ca2+ influx










bFGF: basic fibroblastic growth factor; IGF: insulin-like growth factor, IL: inter-
leukin; IP3: inositol 3-phosphate; JMJ: jumonji domain-containing protein;
MLCK: myosin light chain kinase; MAPK: mitogen activated protein kinase; PG:
prostaglandin; PKC: protein kinase C; PLC: phospholipase C; TNF: tumor necrosis
factor-a·
First we will consider (i) the recent evidence on the altered BNP
production and peripheral metabolism in patients with cardiac dis-
ease, and then (ii) the recent studies concerning the role of the
CNP system on cardiovascular disease. These findings will be then
(iii) set  into context through a comprehensive vision on the role of
endocrine cardiac function and of  the network of NP hormones; and
(iv) considered for their clinical and pharmacological implications.
2. NP hormones: an integrated regulatory system
NP hormones constitute a well-integrated regulatory system
and share a similar structural conformation; they are characterized
by a  peptide ring with a cysteine bridge, which is well preserved
throughout the phylogenetic evolution, being the portion of  the
peptide chain that binds to the specific receptor (Fig. 1). Members
of the NP family are present in both plant and animal kingdoms
[34–38]. In particular, CNP is the ancestral precursor of  the NP fam-
ily and is the most structurally conserved (Fig. 1) [34,37];  it is quite
probable that tandem duplication of  an ancestral CNP gene early in
animal evolution (probably in fish) then originated ANP and BNP
[39]. Indeed, considering the role of NP in fundamental biological
functions, such as the regulation of solute and fluid homeostasis and
cardiovascular function, the NP system must have appeared early
in phylogenesis, potentiating its  biological action through multiple
tandem duplications of  specific genes throughout the evolution of
vertebrates.
Overall, the production of ANP, BNP and CNP is regulated by sim-
ilar (at least in part) intracellular pathways (Fig. 2 and Table 2). Both
ANP and BNP genes are regulated by  the same transcriptional fac-
tors, including p38 mitogen-activated protein kinase (MAPK) [3,5].
In particular, p38 MAPK activates the transcription factor NF-kB and
subsequently transcription of the ANP and BNP genes [3,5]. Putative
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Fig. 1. Natriuretic peptide ancestral gene evolution from amphibian to mammals (modified by Ref. [34]).
biological factors regulating the production/secretion of ANP and
BNP in vivo or in cell culture of cardiomyocytes are summarized
in Table 2. The same transcriptional factors and neuro-endocrine
effectors are likely to also regulate CNP production in several tissues
[40–43].
Similarities also concern the action of ANP, BNP and CNP: they
activate 3  specific components of  the guanylyl cyclase receptor
family that catalyze the conversion of guanosine triphosphate
to cyclic guanosine monophosphate (cGMP) and pyrophosphate
[4,44] (Fig. 2). Intracellular cyclic GMP  is the second messenger
of the guanylyl cyclase receptor family that modulates several
important functions in mammals: platelet aggregation, neuro-
transmission, sexual arousal, gut peristalsis, blood pressure, long
bone growth, intestinal fluid secretion, lipolysis, cardiac hyper-
trophy and oocyte maturation [4,44].  ANP, BNP and CNP can
bind and activate all the 3 guanylyl cyclase receptors, although
with different specificity (Figs. 2 and 3). As a result, the NP hor-
mones share a similar spectrum of  biological actions, although
there are some differences in biological potency among ANP, BNP
and CNP.
Fig. 2. Interaction of ANP, BNP, and CNP with their specific receptor NPR-A (NPR-1, GC-A) NPR-B (NPR-2, GC-B) and  NPR-C (NPR-3). NPR-A and NPR-B are trans-membrane
containing an equally large intracellular domain consisting of  a  kinase homology domain, dimerization domain, and  carboxyl-terminal guanylyl cyclase domain. Differently,
NPR-C  only contains an intracellular domain and  lacks guanylyl cyclase activity.
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Fig. 3. Schematic model of  the structure of the natriuretic peptide receptor sub-
types (NPR-A/GC-A; NPR-B/GC-B and NPR-C) and natriuretic peptides presence in
endothelial cells and cardiomyocytes before being released into blood vessels.
3. Recent insights on production and peripheral
degradation of B-type natriuretic peptides
In human cardiomyocytes, BNP is synthesized as a 134-amino
acid precursor peptide (preproBNP) and is subsequently processed
to form a 108-amino acid propeptide (proBNP). Part of proBNP
is  O-glycosylated within the Golgi apparatus [5,45–48] and is
secreted into the circulation, whereas a remaining part that is
not O-glycosylated may  undergo enzymatic cleavage by cardiomy-
ocyte protein convertases (such as  corin and furin) to form the
76-amino acid N-terminal peptide (i.e., NT-proBNP) and the biolog-
ically active 32-amino acid C-terminal peptide (i.e., BNP) (Fig. 4)  [5].
A smaller part of  intact pro-hormone is nor glycosylated or cleaved,
and can be found into circulation in its intact form as proBNP. Glyco-
sylation on the threonyl residue in position 71 (Thr 71) may regulate
pro-hormone cleavage by either blocking or guiding endoprote-
olytic enzymes [5,48].
Recent studies indicate that the prevalent circulating form
of B-type natriuretic peptides is not, however, the biologically
active peptide BNP. Indeed, chromatographic procedures on plasma
of experimental animals and patients with heart failure evi-
dence a large number of  circulating proBNP-derived fragments
[5,23,24,28,48–50].  Moreover, plasma proBNP and NT-proBNP (and
probably also other shorter peptides derived from these peptides)
are found in both glycosylated and non-glycosylated form (espe-
cially in patients with heart failure) [5,24,25]. Some studies suggest
that proBNP may  be the major B-type NP immunoreactive form
in the human blood, especially in patients with congestive heart
failure [22–24,28]. In particular, Seferian et al. [46] have recently
reported that the plasma pool of endogenous NT-proBNP contains
a small portion (about 5%) of nonglycosylated or incompletely gly-
cosylated protein.
3.1. Pathophysiological, clinical and pharmacological
considerations
Compared to NT-proBNP and proBNP, the active peptide BNP has
a shorter plasma half-life (about 15–20 min  vs 1 or more hours) and
is present in plasma at lower concentration, especially in patients
with heart failure (Table 3 and Fig. 5). Indeed, a 50-fold progressive
increase in median BNP level and a  150-fold increase in median
Fig. 4. Natriuretic peptide gene name, chromosome localization, processing, structure and expression. The final amino acid sequence and  structure of the  mature peptides
along with the major degradation product are shown on the  bottom. The sites of  cleavage are indicated with scissors. BNP, and CNP are mainly expressed in the indicated
tissues  as pre-pro-hormones. The signal sequences are cleaved to form pro-BNP and pro-CNP. The peptides are further proteolytically processed to form mature peptides
(modified from Ref. [4]).
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Table 3
Biochemical and physiological characteristics of  BNP, NT-proBNP and proBNP peptides.
BNP NT-proBNP proBNP
Molecular mass 3462 Da 8457 Da* 11,900 Da*
Amino acids 32 76 108
Biological function Active hormone Inactive Pro-hormone
Half  life 15–20 min  >60 min  >60 min
Glycosylation Not glycosylated Highly glycosylated in  vivo Highly gllycosylated in  vivo
Normal  range** 1–50 ng/L 4–200 ng/L 40–100 ng/L
* The molecular mass (MM)  of  NT-proBNP and proBNP depends to the  degree of glycosylation of the peptide; in  the table are reported the MM  of  not  glycosylated peptides.
** The range values of plasma BNP, NT-proBNP and  proBNP concentrations in  healthy subjects are strongly dependent to the  immunoassay methods used for the measure-
ment, as well as to age, gender and BMI  values [12,22,30,45].  Therefore, the values reported in  the  table should be considered only as indicative.
Fig. 5. BNP and NT-proBNP levels in healthy subjects and  patients with different
clinical severity of heart failure. Top panel: plasma BNP and  NT-proBNP increment
of  median level in 820 patients with stage A–D of heart failure, as compared to
182  healthy subjects median concentration. Bottom panel: plasma BNP and NT-
proBNP increment of median level in  479 stage C and  D patients grouped according
to  NYHA class, as compared to 182 healthy subjects median concentration. The data
reported in the figure clearly demonstrate that patients with heart failure show
higher levels of the inactive NT-proBNP than the biologically active hormone BNP.
Moreover, these data indicate that both plasma BNP and NT-proBNP levels progres-
sively increase according to the severity of  heart failure. Data from our laboratory
(modified from Refs. [51,52]).
NT-proBNP level are observed from healthy subjects to patients
with heart failure in NYHA class IV/stage D (Fig. 5)  [51]. Data
reported in Fig. 5 indicate that asymptomatic patients in stage B
(i.e., symptomatic patients at risk for developing heart failure with
structural cardiac involvement) [18], on average, have higher BNP
and NT-proBNP levels than apparently healthy subjects. Further-
more, symptomatic patients with moderate systolic heart failure,
such as those in class NYHA class I,  show also significantly higher
levels of NP than apparently healthy subjects (Fig. 5). These find-
ings represent the rationale for evaluating the diagnostic accuracy
of BNP and NT-proBNP levels in screening programs including gen-
eral population or primary care patients [51,52]. Moreover, some
recent studies reported that patient with heart failure have also
greatly increased circulating proBNP levels compared to healthy
subjects [22,26–28]. From a pathophysiological point of view, a
blunted natriuretic response after pharmacological doses of  ANP
and BNP has been observed in experimental models and in patients
with chronic heart failure, suggesting a resistance to the biological
effects of NP, mainly to natriuresis [3]. As mentioned above [3],
resistance to the biological action of  NP can be attributed to at least
three kinds of different causes/mechanisms, acting at pre-receptor,
receptor, and post-receptor level, respectively.
Based on recent findings [19–28,49,50,53–55],  resistance at the
pre-receptor level in  patients with heart failure could be explained
by an insufficient post-translation maturation of the biosynthetic
precursors of  B-type natriuretic peptide system. Accordingly, it
is theoretically conceivable that the active hormone (i.e., BNP)
could be produced even in vivo from the circulating precursor
proBNP1-108 by plasma enzyme degradation [19–28,49,50,53–55].
Indeed, the soluble form of corin, a transmembrane serine protease
able to cleave proBNP, is also capable of processing the circulat-
ing intact precursor of  natriuretic hormones [53,54].  Dong et al.
[54] recently confirmed that soluble corin is detectable in human
blood. Furthermore, these authors report that levels of plasma
corin are significantly lower in patients with heart failure than
in healthy controls, and that the reduction in plasma enzyme is
correlated to the severity of  the disease [54].  Finally, Semenov
et al. demonstrated that synthetic or recombinant human proBNP
can be processed to active BNP in the circulating blood, when
injected in the femoral vein of rats [55]. On the other hand recent
results indicate that proBNP may bind and also activate the spe-
cific receptor of NP (i.e., the guanylyl cyclase-A, also named NPR-A),
although with reduced efficacy compared to ANP and BNP [56]. As
a result, proBNP should be considered to be a low efficacy ago-
nist compared to biologically active hormone BNP, in this way
contributing to the reduced NP response in patients with heart fail-
ure. Indeed, reduced degradation of proBNP may  contribute to the
increased proBNP:BNP ratio observed in patients with congestive
heart failure, consequently explaining (almost in part) the periph-
eral resistance to biological action of NP [57].
Peripheral processing of circulating proBNP seems to be sub-
mitted to regulatory rules that are impaired in patients with
heart failure. If this were to be confirmed, such hypothesis would
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Fig. 6. (a) Distribution of CNP and NT-pro-CNP plasma levels in chronic heart failure patients as a  function of  disease severity. Each box consists of 5 horizontal lines displaying
the 10th, 25th, 50th (median), 75th, and 90th percentiles of the variable. All values above the  90th percentile and below the 10th percentile are plotted separately (modified
by  Ref. [76]). (b) CNP mRNA expression measured by Real Time PCR in  human whole blood of HF patients as a function of  clinical severity (modified by Ref. [90]).
open new perspectives even in  the treatment of heart failure
[2,20,21,29,30,58], and could identify novel pharmacological tar-
gets for drugs inducing and/or modulating the maturation of the
prohormone into active hormone (i.e., BNP) [2,29,58].  In conclusion,
these studies, taken together, strongly indicate that the prevalent
amount of the circulating B-type natriuretic peptides in patients
with heart failure lacks biological activity. These results open the
question about the possible regulation of  the peripheral processing
of circulating proBNP. Based on this hypothesis, several authors
suggested the biologically active BNP can be produced also in blood
from proBNP plasma pool. Accordingly, plasma proBNP should be
considered to be also a circulating precursor of the biologically
active hormone, BNP [2,5,20,25,30,58]. In other words, BNP may
be produced from the precursor proBNP in  both cardiomyocytes
and blood.
4. Recent insights on production, structure and release of
C-type natriuretic peptide
First isolated from porcine brain in 1990 [59] CNP, is the
most expressed natriuretic peptide in the brain; it is also widely
expressed throughout the vasculature and is found in particularly
high concentrations in the endothelium, where it plays a role in the
local regulation of vascular tone [60–62].  It is stored inside endothe-
lial cells and is able to induce vasorelaxation by hyperpolarization,
suggesting that CNP may be an endothelium-derived hyperpolar-
izing factor (EDHF), participating in the paracrine action of other
endothelial vasorelaxant mediators, such as nitric oxide (NO) and
prostacyclin [63–65]. Recently, CNP expression was also found in
cardiomyocytes at both gene and protein levels [66]. The human
gene encoding for CNP, NPPC (GeneID 4880), is located on  chromo-
some 2 and encodes a  polypeptide of 126 amino acids, with a 23
amino acid signal sequence followed by a 103 amino acid proCNP
[67,68].  PreproCNP shows remarkable homology between species
and the circulating 22 amino acid carboxyl terminal form is abso-
lutely identical in chimpanzees, dogs, mice, and rats species [68]
(Fig. 1).
Processing of proCNP to its mature form may occur through the
action of  the intracellular serine endoprotease, furin. In vitro, furin
cleaves the 103 amino acid proCNP into a 53 amino acid carboxyl-
terminal biologically active peptide (CNP-53), that is the major
active form of CNP at tissue level [69,70] (Fig. 4). In the systemic cir-
culation, a shorter 22 amino acid form dominates (CNP-22) but the
protease responsible for this cleavage is not known. Importantly,
CNP-53 and CNP-22 appear to bind and activate their specific recep-
tor, NPR-B, equally well [70,71]. CNP is not stored in  granules and
its secretion is increased by growth factors [72,73] and shear stress
[74]. The clearance of CNP-22 in human plasma is very rapid, with
a calculated half-life of 2.6 min  [75,76].
4.1. Clinical relevance of C-type natriuretic peptide in heart
failure
The involvement of CNP in cardiovascular disease has been
recently taking on an increasingly important role. Several stud-
ies carried out in  humans have reported increased NT-proCNP
[77,78] and CNP plasma levels in patients with chronic heart
failure compared to healthy subjects [77,79–83]. Data reported
in Fig. 6a indicate a  progressive plasma increase of both CNP
and NT-proCNP in function of clinical severity. Because of (i)  the
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progressive rise in CNP and NT-proCNP plasma values with the
worsening of symptoms [77,79–81] and (ii) the negative rela-
tion between plasma CNP values and left ventricular ejection
fraction [81],  such increase in secretion appears to be related
to the severity of the disease. Moreover, this increase in CNP
plasma concentrations in parallel to worsening clinical severity
could be a compensatory effect in response to cardiac dysfunc-
tion; together with the other natriuretic peptides ANP and BNP,
CNP probably contributes to neuro-hormonal activation (which is a
hallmark of chronic heart failure) counteracting the predominance
of vasoconstrictor and sodium retentive systems (sympathetic,
rennin–angiotensin–aldosterone, vasopressin and endothelin sys-
tems) [81,82].
Recent studies indicate that the production of C-type natri-
uretic peptides, especially in patients with heart failure directly
involves the heart and, namely, the myocardium [79,84–88]. In fact,
immunohistochemistry and radioimmunoassay techniques within
the myocardium demonstrate that CNP cardiac expression is two to
three times higher in patients with chronic heart failure compared
to  controls [66];  in particular, CNP levels in patients with chronic
heart failure are significantly increased in the coronary sinus, as
compared to the aorta [84,85].
From a pathophysiological point of view, CNP also carries out an
important autocrine and paracrine function in pathophysiological
cardiac remodeling [84,85].
Studies carried out by bimolecular technique both in animals
model [86,88] that in human leukocytes [89,90] permitted to detect
the mRNA expression of  CNP and NPR-B in normal myocardial tis-
sue as well as in human whole blood samples of healthy subjects.
The studies on minipigs have reported myocardial alterations in
the expression of CNP and NPR-B in normal and failing hearts
[86–88], moreover an increase of CNP and NPR-B transcriptomic
profiling was observed in human whole blood samples of heart
failure patients [89] and in a recent paper [90] original data rel-
ative to CNP mRNA increase as a function of clinical severity in
parallel with a down-regulation of  NPR-B expression in  patients
with worsening of symptoms was reported (Fig. 6b). Hence CNP
could have a behavior similar to BNP, underlining the importance of
the endocrine role of myocardium in the generation of CNP during
early left ventricular dysfunction [86–88]. In particular the studies
showed a CNP protein and gene expression detected in tissue of
normal and failing hearts, along with an increased myocardial CNP
synthesis in the presence of the NPR-B down-regulation in failing
heart [86]. The presence of CNP in cardiac tissue would suggest a
possible synergistic effect with the other natriuretic cardiac pep-
tides, ANP and BNP [91]. Moreover, recent studies have found CNP
expression in cardiomyocytes, both at the gene and protein lev-
els, as well as NPR-B mRNA expression [66]. This co-localization
of the peptide and its  specific receptor NPR-B in cardiomyocytes
suggests the heart to be actively involved in the production of CNP,
reinforcing its involvement in cardiovascular pathophysiology.
Taken together, these studies indicate that CNP is produced
in the heart during cardiac failure, where it may elicit important
compensatory physiological consequences in  ventricular remod-
eling. Positive effects of  CNP on  cardiac contractility, lusitropy
and dromotropy have been also described in several studies
using intact animals, isolated hearts, cardiac muscle preparations
and isolated cardiomyocytes [92].  At present, however, evidence
toward cardioprotective effects of CNP is controversial. Studies
have reported that activation of the CNP/NPR-B pathway follow-
ing myocardial infarction promotes apoptosis of cardiomyocytes
[93] and mediates anti-proliferative and anti-hypertrophic effects
in adult cardiac cells [32,94]; furthermore, in infarct remodeled
myocardium, expression of CNP is locally increased in the presence
of a dense capillary network [95].  In rats, in vivo administration of
CNP improves cardiac function and attenuates cardiac remodeling
after myocardial infarction. It is hypothesized that this effect on  car-
diac remodeling is due to CNP anti-fibrotic and anti-hypertrophic
actions, which would identify this peptide as a useful novel anti-
remodeling pharmacological agent [94,96]. In addition, given the
inhibitory effects of CNP on cardiac fibrosis and hypertrophy in
vitro, CNP could operate against the progression of late cardiac
remodeling after myocardial infarction [96].
Finally, CNP appears to also be potentially involved in the renal
natriuretic peptide system, which participates in the regulation of
sodium and water balance and the renal circulation [84]. In fact, in
patients with heart failure also the renal CNP system is activated
and urinary excretion of  CNP is significantly increased [97].
5. Pharmacological and clinical perspectives and
conclusion
Despite the remarkable advances in the knowledge on cardiac
endocrine function and the NP network, which have been nar-
rowing focus toward specific pharmacologic targets, there are still
many aspects that need to be solved.
In first instance, the production, secretion and peripheral degra-
dation pathways of  both B-  and C-type natriuretic peptides, still
need to be confirmed, clarifying in particular the hypothesis of
whether the circulating plasma pool of the pro-hormone can actu-
ally function as precursor of  the active peptide hormone.
Another important unsolved question concerns the use of NP
as therapeutic agents in heart failure [98–100]. Hospitalization for
heart failure is a  clinical entity associated with high post discharge
morbidity and mortality [100,101].  Unfortunately, few therapies
are available to improve outcomes in patients with this condition
[100].  In the first years of  the new century, the anti-fibrotic and
remodeling effects of NP suggested the use of  some analogs of BNP
(like as Nesiritide, a recombinant human BNP) as therapeutics in
heart failure [98–100].  The initial enthusiasm for the parenteral
(IV infusion) administration of NP analogs was soon attenuated by
the appearance of  some adverse effects (such as severe hypoten-
sion) on survival and renal function [98–100]. However, a pilot
study [102] has recently suggested that subcutaneous administra-
tion of  BNP (instead of IV infusion) may  represents a novel, safe,
and efficacious protein therapeutic strategy in patients with heart
failure.
Although several clinical trials have documented the benefits
and risks of  the use of synthetic ANP (Anaritide), BNP (Nesiritide)
and urodilatin (Ularitide) in patients with cardiovascular and renal
diseases [103,104],  to our knowledge, only few clinical studies have
been reported on the use of  some CNP analogs for the treatment of
heart failure. An innovative approach may  be to create “designer”
chimeric peptides, which hold the possibility to extend both the
application and therapeutic benefits possible with a natriuretic
peptide based approach [105]. For example, CD-NP is a chimeric
peptide consisting of CNP and part of DNP [105–107]. This peptide
was shown to possess cyclic guanosine monophosphate-activating,
natriuretic, and aldosterone suppressing properties without induc-
ing excessive hypotension when given to healthy subjects [105].
This preliminary study may  pave the way  for further clinical trials.
The administration of some oral agents, which are able to
modulate the production and/or degradation of active hormones
in the circulation, may  have some beneficial effects on  cardiac
remodeling without affecting cardiovascular hemodynamics. In
particular, inhibition of the neutral endopeptidase had been inves-
tigated as a potential novel therapeutic approach because of its
ability to increase the plasma concentrations of NP in combination
with other cardiovascular agents, such as angiotensin-converting
enzyme inhibitors, and antagonists of the angiotensin receptor
[101]. These data once more underline the close link between
S. Del Ry et al. / Pharmacological Research 76 (2013) 190– 198 197
the NP system and the network including endocrine, nervous and
immune systems.
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